---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010152"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T17:58:49.332563+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera reports record FY2023 revenue of $34.1M, +19% YoY; Q4 net income $3.5M

## Summary
- FY2023 total revenues $34.1M (+19% YoY); operating expenses $56.7M (incl $2M one-time legal).
- Q4 2023 revenue $10.6M (+4% YoY); net income $3.5M ($1.65/shr) vs loss $2.8M ($2.16 loss/shr) in Q4 2022.
- Adjusted EBITDA for Q4 negative $3.2M (improved from negative $4.4M in prior year).
- Submitted sNDA to increase Ameluz use to 3 tubes for AK; PDUFA Oct 4, 2024. Phase 3 enrollment for sBCC completed.
- Restructured LSA to cut transfer price to 25% for 2024-2025; acquired patents for new portable PDT lamp.

## SEC filing metadata
- accession: 0001493152-24-010152
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010152
- JSON: https://secwatch.observer/filing/0001493152-24-010152.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010152.txt

## Key facts
- Earnings Releases
  Biofrontera Inc. reported the fourth quarter of 2023 results: revenue $10.6 million, net income $3.5 million, EPS $1.65 per share.
  - Period: the fourth quarter of 2023
  - Revenue: $10.6 million
  - Net income: $3.5 million
  - EPS: $1.65 per share
  - Result: reported results
  source text: Total revenues for the fourth quarter of 2023 were $10.6 million, an increase of $0.5 million, or ~4%, compared with $10.1 million for the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm
- Earnings Releases
  Biofrontera Inc. reported financial results for the three and twelve months ended December 31, 2023.
  - Period: the three and twelve months ended December 31, 2023
  - Result: reported results
  source text: On March 15, 2024, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.